| Code | CSB-RA004956MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Milatuzumab, targeting CD74 (also known as HLA class II histocompatibility antigen gamma chain or invariant chain). CD74 is a type II transmembrane glycoprotein that serves as a chaperone for MHC class II molecules, facilitating their proper folding and peptide loading in antigen-presenting cells. Beyond its role in antigen presentation, CD74 functions as a receptor for macrophage migration inhibitory factor (MIF), regulating immune cell survival and inflammatory responses. CD74 is aberrantly expressed in various B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma, making it an important therapeutic target in hematologic cancers.
Milatuzumab is a humanized IgG1 anti-CD74 monoclonal antibody that has been investigated in clinical trials for B-cell malignancies due to its ability to induce antibody-dependent cellular cytotoxicity and promote tumor cell apoptosis. This biosimilar antibody provides researchers with a valuable tool for investigating CD74-mediated signaling pathways, immune regulation, and potential therapeutic mechanisms in oncology and immunology research.
There are currently no reviews for this product.